FI954383A - Menetelmä syöpärokotteiden valmistamiseksi - Google Patents

Menetelmä syöpärokotteiden valmistamiseksi Download PDF

Info

Publication number
FI954383A
FI954383A FI954383A FI954383A FI954383A FI 954383 A FI954383 A FI 954383A FI 954383 A FI954383 A FI 954383A FI 954383 A FI954383 A FI 954383A FI 954383 A FI954383 A FI 954383A
Authority
FI
Finland
Prior art keywords
preparation
cancer vaccines
vaccines
cancer
Prior art date
Application number
FI954383A
Other languages
English (en)
Swedish (sv)
Other versions
FI954383A0 (fi
Inventor
Max L Birnstiel
Michael Buschle
Matthew Cotten
Gerhard Maass
Christian Plank
Gotthold Schaffner
Walter Schmidt
Ernst Wagner
Kurt Zatloukal
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0055693A external-priority patent/AT399656B/de
Priority claimed from DE4326821A external-priority patent/DE4326821A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of FI954383A publication Critical patent/FI954383A/fi
Publication of FI954383A0 publication Critical patent/FI954383A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI954383A 1993-03-19 1995-09-18 Menetelmä syöpärokotteiden valmistamiseksi FI954383A0 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0055693A AT399656B (de) 1993-03-19 1993-03-19 Verfahren zur herstellung von krebsvakzinen
DE4326821A DE4326821A1 (de) 1993-08-10 1993-08-10 Verfahren zur Herstellung von Krebsvakzinen
PCT/EP1994/000859 WO1994021808A1 (de) 1993-03-19 1994-03-18 Verfahren zur herstellung von krebsvakzinen

Publications (2)

Publication Number Publication Date
FI954383A true FI954383A (fi) 1995-09-18
FI954383A0 FI954383A0 (fi) 1995-09-18

Family

ID=25593140

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954383A FI954383A0 (fi) 1993-03-19 1995-09-18 Menetelmä syöpärokotteiden valmistamiseksi

Country Status (13)

Country Link
EP (1) EP0689604A1 (fi)
JP (1) JPH08507921A (fi)
KR (1) KR960701211A (fi)
CN (1) CN1119459A (fi)
AU (1) AU6427994A (fi)
CA (1) CA2158655A1 (fi)
CZ (1) CZ241795A3 (fi)
FI (1) FI954383A0 (fi)
HU (1) HUT73383A (fi)
NO (1) NO953684L (fi)
NZ (1) NZ263550A (fi)
PL (1) PL311036A1 (fi)
WO (1) WO1994021808A1 (fi)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093700A (en) 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
DE69535288T2 (de) * 1994-05-13 2007-04-05 Thomas Jefferson University Verfahren zur induzierung einer immunantwort mittels rekombinanten vaccinia-viren, die das gm-csf-gen exprimieren
DE4426429A1 (de) * 1994-07-26 1996-02-01 Boehringer Ingelheim Int Verfahren zum Einführen von DNA in höhere eukaryotische Zellen
DE19510344C1 (de) * 1995-03-22 1996-11-07 Boehringer Ingelheim Int Verwendung einer Tumorvakzine
AU6282896A (en) * 1995-06-19 1997-01-15 University Of Medicine And Dentistry Of New Jersey Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins
US7001765B2 (en) 1996-03-06 2006-02-21 Medigene Ag Adeno-associated virus vector for boosting immunogenicity of cells
DE19608753C1 (de) * 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
DE19608751B4 (de) 1996-03-06 2006-05-18 Medigene Ag Verwendung eines Adeno-assoziierten Virus-Vektors zur Steigerung der Immunogenität von Zellen
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
DE69840524D1 (de) * 1997-08-13 2009-03-19 Uab Research Foundation Impfung durch topische verwendung genetischer vektoren
CA2299429C (en) 1997-08-13 2010-04-20 Biontex Laboratories Gmbh New lipopolyamines,their preparation and the use thereof
US7348015B2 (en) 1998-01-14 2008-03-25 Morphogenesis, Inc. Antigen modified cancer cell vaccines for cancer therapy
US7795020B2 (en) 1998-01-14 2010-09-14 Morphogenesis, Inc. Tumor cell vaccines
WO1999036433A2 (en) 1998-01-14 1999-07-22 Morphogenesis, Inc. Materials and methods for treating oncological disease
JP4768122B2 (ja) 1998-02-20 2011-09-07 ユニバーシティー オブ マイアミ 改変型熱ショックタンパク質−抗原性ペプチド複合体
CN100425287C (zh) * 1999-02-09 2008-10-15 理化学研究所 肿瘤疫苗
BR0001029A (pt) * 2000-04-10 2001-11-20 Fk Biotecnologia Ltda Processo de transformação de células tumorais
AUPQ755300A0 (en) 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
DE10131148A1 (de) * 2001-06-28 2003-01-16 I P L Internat Pharmaceutics L Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
AU2009223838B2 (en) 2008-03-03 2012-07-26 The University Of Miami Allogeneic cancer cell-based immunotherapy
CA2718884C (en) 2008-03-20 2016-11-22 University Of Miami Heat shock protein gp96 vaccination and methods of using same
NZ611361A (en) * 2010-12-02 2014-10-31 Oncotherapy Science Inc Tomm34 peptides and vaccines including the same
AU2016215175B2 (en) 2015-02-06 2021-09-16 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
US11273170B2 (en) * 2016-07-25 2022-03-15 Ascend Biopharmaceuticals Ltd Methods of treating cancer
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
SG11202005934WA (en) * 2017-12-29 2020-07-29 Genemedicine Co Ltd Cell sheet for gene delivery

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation

Also Published As

Publication number Publication date
EP0689604A1 (de) 1996-01-03
NZ263550A (en) 1996-12-20
NO953684D0 (no) 1995-09-18
HUT73383A (en) 1996-07-29
CN1119459A (zh) 1996-03-27
PL311036A1 (en) 1996-01-22
NO953684L (no) 1995-09-18
HU9502720D0 (en) 1995-11-28
CA2158655A1 (en) 1994-09-29
CZ241795A3 (en) 1996-04-17
WO1994021808A1 (de) 1994-09-29
JPH08507921A (ja) 1996-08-27
AU6427994A (en) 1994-10-11
FI954383A0 (fi) 1995-09-18
KR960701211A (ko) 1996-02-24

Similar Documents

Publication Publication Date Title
FI954383A (fi) Menetelmä syöpärokotteiden valmistamiseksi
FI103967B1 (fi) Menetelmä tetrahydrokarbatsonijohdannaisten valmistamiseksi
FI945441A (fi) Uusi menetelmä 7beta-substituoitu-4-atsa-5alfa-androstan-3-onien valmistamiseksi
FI960278A (fi) Anataasititaanidioksidin valmistusmenetelmä
FI103666B1 (fi) Menetelmä bifenyylijohdannaisen valmistamiseksi
FI962370A0 (fi) Laite tissuen valmistamiseksi
FI892058A0 (fi) Fenolin valmistusmenetelmä
FI940769A (fi) Menetelmä 2-aminoatsolijohdannaisten valmistamiseksi
FI952585A (fi) Menetelmä bentsopyraaniyhdisteiden valmistamiseksi
FI942907A (fi) Menetelmä lipaasin valmistamiseksi
FI954272A0 (fi) Menetelmä akryylipiperidiinikarbinolien valmistamiseksi
FI902316A0 (fi) Menetelmä valmistaa terapeuttisesti vaikuttavia substituoituja dihydropyrrolitsiiniyhdisteitä
FI102270B1 (fi) Menetelmä dieettereiden valmistamiseksi
FI942102A0 (fi) Menetelmä alumiinioksaanien valmistamiseksi
FI964229A0 (fi) Menetelmä doksorubisiinin valmistamiseksi
FI911701A (fi) Menetelmä terapeuttisesti käyttökelpoisten 2-substituoitujen alkyyli-3-karboksikarbapeneemien valmistamiseksi
NO941056L (no) Fremgangsmåte for fremstilling av organoklorsilaner
FI956058A (fi) Menetelmä glutaaridialdehydin valmistamiseksi
FI942394A0 (fi) Menetelmä steroidiperasyyliglykosidien valmistamiseksi
FI961178A (fi) Menetelmä syklisten cis-1-amino-2-alkanolien valmistamiseksi
FI892144A (fi) Menetelmä 5-C-hydroksimetyylialdoheksoosipohjaisten yhdisteiden valmistamiseksi
FI102841B1 (fi) Menetelmä mannitolin valmistamiseksi
FI940551A0 (fi) Menetelmä fenyylibentsamidijohdannaisten valmistamiseksi
FI971964A0 (fi) Menetelmä 1-halo-3-trialkyylisilasnyylibentseenijohdannaisten valmistamiseksi
FI943660A0 (fi) Menetelmä 3-karbonyyliandrostadieeni-17-karboksamidien valmistamiseksi